In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Ohara Pharmaceutical Co., Ltd.

http://www.ohara-ch.co.jp/english/index.html

Latest From Ohara Pharmaceutical Co., Ltd.

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Financing Neurology

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom

Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.

Financing StartUps and SMEs

BTG Gains First U.S. Approval With Methotrexate Antidote Voraxaze

Transatlantic specialty pharma BTG adds to its antidote portfolio with FDA approval of Voraxaze, an enzyme drug that breaks down methotrexate in patients whose kidneys are failing due to high serum levels of the chemotherapeutic. BTG also markets snake-bite therapy CroFab and DigiFab for digitalis overdose and recently licensed a late-stage drug to counter toxicity from 5-FU chemotherapy.

BioPharmaceutical

EUSA Wins U.S. Approval of Erwinaze; Shipping To Start Week Of Nov. 20

Eusa hopes the approval will help cement its efforts in the U.S., where it has been trying to build a strong presence for several years.

BioPharmaceutical Launches
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
UsernamePublicRestriction

Register